Search found 81 matches
- 10-Jan-2023, 23:05
- Forum: Hardware, DIY (Do-It-Yourself)
- Topic: How to swap bytes in MCU
- Replies: 0
- Views: 10513
How to swap bytes in MCU
/// Network to host byte order conversion. #if defined (__CC_ARM) // ARM Compiler 4/5 #define ntohl(v) (uint32_t)(__rev(v)) #define ntohs(v) (uint16_t)(__rev(v) >> 16) #else // ARM Compiler 6 #define ntohl(v) __builtin_bswap32((uint32_t)(v)) #define ntohs(v) __builtin_bswap16((uint16_t)(v)) #endif ...
- 10-Jan-2023, 22:56
- Forum: Hardware, DIY (Do-It-Yourself)
- Topic: [Error] How to fix ARMCLANG no FPU warning for Cortex-M1
- Replies: 0
- Views: 10877
[Error] How to fix ARMCLANG no FPU warning for Cortex-M1
When you get a warning in Keil uVision compiler: #warning "Compiler generates FPU instructions for a device without an FPU (check __FPU_PRESENT)" you should set compilers' floating point option: -mfloat-abi=soft Other possible options: soft - Software library functions for floating-point operations ...
- 16-Nov-2022, 15:59
- Forum: Health, Medicine, Therapy
- Topic: miRecule and Sanofi will develop muscular dystrophy therapy with MC-DX4
- Replies: 0
- Views: 10067
miRecule and Sanofi will develop muscular dystrophy therapy with MC-DX4
miRecule and Sanofi accelerate discovery and development of a best-in-class Antibody-RNA conjugate (ARC) to treat Facioscapulohumeral Muscular Dystrophy ( FSHD ). Partnership combines miRecule’s unique RNA therapeutic discovery and conjugation platforms with Sanofi’s NANOBODY® technology to create ...
- 23-Aug-2022, 21:39
- Forum: Health, Medicine, Therapy
- Topic: FSH Testing at no cost
- Replies: 0
- Views: 10420
FSH Testing at no cost
Dr. Peter Jones and Dr. Takako Jones (at the University of Nevada) are conducting a research project to improve facioscapulohumeral muscular dystrophy (FSHD) diagnostics and to better understand the genetics and epigenetics of FSHD. Current genetic testing for FSHD, where available, is a complicated...
- 20-Aug-2022, 16:45
- Forum: Hardware, DIY (Do-It-Yourself)
- Topic: Подключение cиловой нагрузки к микроконтроллеру.
- Replies: 3
- Views: 38542
Re: Подключение cиловой нагрузки к микроконтроллеру.
Подключение нагрузки с помощью полевого транзистора. Затвор полевого транзистора должен быть зафиксирован в каком-либо состоянии. Для этой цели обычно используется высокоомный подтягивающий (стягивающий) резистор на землю GND. Если ёмкость затвора большая, то для защиты порта от большого тока следу...
- 21-Jun-2022, 21:58
- Forum: Health, Medicine, Therapy
- Topic: Dyne Therapeutics approach to treating muscular dystrophy
- Replies: 0
- Views: 10785
Dyne Therapeutics approach to treating muscular dystrophy
Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. Our proprietary FORCE(TM) platform drives our efforts to develop targeted, modern oligonucleotide therapeutics with the po...
- 21-Jun-2022, 21:26
- Forum: Health, Medicine, Therapy
- Topic: FSHD Diagnostic Assay
- Replies: 0
- Views: 10200
FSHD Diagnostic Assay
The FSHD FiberProbes® are designed for the genetic diagnosis of FSHD-1 . They enable the characterization of the 3.3 kb-D4Z4 repeats and the qA/qB haplotype sequences located in the subtelomeric regions of chromosomes 4 and 10, thanks to the hybridization of fluorescent probes on single DNA molecule...
- 21-Jun-2022, 21:19
- Forum: Health, Medicine, Therapy
- Topic: Avidity Biosciences presents preclinical data from FSHD program
- Replies: 0
- Views: 10275
Avidity Biosciences presents preclinical data from FSHD program
June 17, 2022 – Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), joins in activities to raise awareness for Facioscapulohumeral muscular dystrophy (FSHD) in support of World FSHD Day and...
- 21-Jun-2022, 20:55
- Forum: Health, Medicine, Therapy
- Topic: [Info] Losmapimod
- Replies: 0
- Views: 10033
[Info] Losmapimod
Losmapimod is an investigational, selective p38α/β mitogen activated protein kinase (MAPK) inhibitor. Fulcrum exclusively in-licensed losmapimod from GSK following Fulcrum’s discovery of the role of p38α/β inhibitors in the reduction of DUX4 expression and an extensive review of known compounds. Re...
- 21-Jun-2022, 20:52
- Forum: Health, Medicine, Therapy
- Topic: Fulcrum announces Phase 3 trial of losmapimod
- Replies: 0
- Views: 10117
Fulcrum announces Phase 3 trial of losmapimod
March 03, 2022 — Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced its plans to initiate a Phase 3 clinical trial of losmapimod in people with facioscapulohumeral muscular dystrophy (FSHD) , in the second quarter of 2022. FSHD is a serious, rare, progressive dis...